Race/Ethnicity
AASLD 2012: Is a Simple Sofosbuvir + Ribavirin Regimen Suitable for Hard-to-treat HCV Patients?
- Details
- Category: HCV Treatment
- Published on Wednesday, 05 December 2012 00:00
- Written by Liz Highleyman
An all-oral dual regimen of sofosbuvir plus full-dose ribavirin was well-tolerated and produced 4-week post-treatment sustained response in approximately three-quarters of previously untreated genotype 1 chronic hepatitis C patients in an inner-city pilot study, researchers reported at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) last month in Boston. Reducing the ribavirin dose, however, lowered response rates.
Racial Differences in Eligibility for Hepatitis C Treatment
- Details
- Category: HCV Treatment
- Published on Tuesday, 02 August 2011 00:00
- Written by James Learned
Black hepatitis C patients were significantly more likely to be deemed ineligible for treatment, primarily due to neutropenia and uncontrolled medical conditions, according to a recent study. Less strict neutrophil eligibility criteria and more effective care for chronic diseases would increase access to HCV treatment for black people.
African Americans with Hepatitis C Have Worse Outcomes than White Patients after Liver Transplantation
- Details
- Category: Liver Transplant/Artificial Liver
- Published on Tuesday, 15 December 2009 12:46
- Written by AASLD
African-American individuals who undergo liver transplants due to complications of hepatitis C virus (HCV) infection experience more rapid post-transplant fibrosis progression and histological inflammation compared with white patients, even though they tend to experience slower pre-transplant disease progression, according to a study presented at the recent 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2009) in Boston.
Web Design and Development by